GGrantIndex
Sort

15,842 grants matching pancreatic cancer

Biology and Immunology of Pancreatic Cancer Stem Cells in a Novel Mouse Model

$470,159
Edgar G. Engleman · Stanford University · U01 · FY2011 · CA

Phase I/II clinical evaluation of ABTL0812, a novel PI3K/Akt/mTOR inhibitor, with a unique mechanism of action inpancreatic cancer (Protocol sent on 20th June 2019 as an amendment of the IND 137394)

$470,000
Davendra Sohal · University Of Cincinnati · R01 · FY2020 · FD

Confocal imaging resources for the JHU Zebrafish Center

$469,986
Steven D Leach · Johns Hopkins University · S10 · FY2010 · RR

TOR signaling and autophagy in obesity-promoted liver tumorigenesis

$469,980
Michael Karin · University Of California, San Diego · R01 · FY2014 · CA

Pixel-accurate oncologic therapy using a scanning fiber endoscope

$469,897
Eric J Seibel · University Of Washington · R01 · FY2010 · EB

NGF recruits nerve fibers to reprogram an immunosuppressive microenvironment in melanoma

$469,848
Xiao-Fan Wang · Duke University · R01 · FY2021 · CA

Stroma Breaking Theranostic Nanoparticle for Targeted Pancreatic Cancer Therapy

$469,682
Lily Yang · Emory University · U01 · FY2019 · CA

Consortium for the study of chronic pancreatitis, diabetes and pancreatic cancer: Pittsburgh Clinical Center

$469,495
Dhiraj Yadav · University Of Pittsburgh At Pittsburgh · U01 · FY2020 · DK

Consortium for the study of chronic pancreatitis, diabetes and pancreatic cancer: Pittsburgh Clinical Center

$469,495
Dhiraj Yadav · University Of Pittsburgh At Pittsburgh · U01 · FY2021 · DK

Targeting tumor architecture as a novel therapeutic strategy for pancreatic cancer

$469,327
Matteo Ligorio · Ut Southwestern Medical Center · R37 · FY2025 · CA

Lysyl Oxidase Propeptide: Breast Cancer Inhibitor

$469,312
Gail E Sonenshein · Tufts University Boston · R01 · FY2013 · CA

A Fragment-Based Strategy for K-RAS Covalent Inhibitors

$469,217
Samy Meroueh · Indiana University Indianapolis · R01 · FY2021 · CA

RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing

$469,135
Karen M Mann · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA

Gut pathogen virulence and its therapeutic modulation during surgical injury

$469,029
John C. Alverdy · University Of Chicago · R01 · FY2023 · GM

Multifactor risk scores with susceptibility gene mutations to enhance risk assessment of pancreatic cancer

$468,867
Ann Laura Oberg · Mayo Clinic Rochester · R01 · FY2023 · CA

The Texas-Louisiana Alliance to Study Chronic Pancreatitis, Diabetes and Pancreatic Cancer

$468,829
Suresh T. Chari · University Of Tx Md Anderson Can Ctr · U01 · FY2020 · DK

GENOMICS OF APOPTOSIS &ANGIOGENESIS IN ISLET CARCINOMA

$468,795
University Of California San Francisco · R01 · FY2000 · CA

Role of Neurogenic Inflammation in Pancreatic Cancer

$468,647
Brian M Davis · University Of Pittsburgh At Pittsburgh · R01 · FY2015 · CA

TGFB-SMAD Signaling in Stem Cell Differentiation and Tumor Suppression

$468,594
Joan Massague · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA

TGFB-SMAD Signaling in Stem Cell Differentiation and Tumor Suppression

$468,594
Joan Massague · Sloan-Kettering Inst Can Research · R01 · FY2015 · CA

TGFB-SMAD Signaling in Stem Cell Differentiation and Tumor Suppression

$468,594
Joan Massague · Sloan-Kettering Inst Can Research · R01 · FY2016 · CA

TGFB-SMAD Signaling in Stem Cell Differentiation and Tumor Suppression

$468,594
Joan Massague · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA

Universal Internal Standard for Reproducible Accurate Quantification of Exosome Protein Markers

$468,551
David M. Lubman · University Of Michigan At Ann Arbor · R01 · FY2023 · CA

Whole Genome Scan in the Pancreatic Cancer Cohort Consortium (PanScan)

$468,522
Rachael Stolzenberg-Solomon · Division Of Cancer Epidemiology And Genetics · ZIA · FY2013 · CA

Prospective Study of Human Oral Microbiome and Pancreatic Cancer Risk

$468,512
Jiyoung Ahn · New York University School Of Medicine · R01 · FY2017 · CA